Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Demonstrate significant bleed reduction in hemophilia A and B
Subscribe To Our Newsletter & Stay Updated
